Femasys Inc.

NasdaqCM FEMY

Femasys Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

Femasys Inc. Debt to Equity Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Femasys Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.08, a 94.99% change year over year.
Femasys Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.04.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqCM: FEMY

Femasys Inc.

CEO	Ms. Kathy Lee-Sepsick M.B.A.
IPO Date	June 18, 2021
Location	United States
Headquarters	3950 Johns Creek Court
Employees	32
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Clinical Trials Cosmetics Medical Instruments Personal Care Pharmaceuticals

Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Key trends

Past 5 years